The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial

Triadafilopoulos, George; DiBaise, John K.; Nostrant, Timothy T.; Stollman, Neil; Anderson, Paul K.; Wolfe, M. Michael; Rothstein, Richard I.; Wo, John M.; Corley, Douglas A.; Patti, Marco G.; Antignano, Louis V.; Goff, John S.; Edmundowicz, Steven A.; Castell, Donald O.; Rabine, John C.; Kim, Michael S.; Utley, David S.

doi:10.1067/mge.2002.121227

Cited by 246 publications

(184 citation statements)

References 19 publications

Supporting

Mentioning

162

Contrasting

Unclassified

Order By: Relevance

“…Similar results were shown in another trials with minor complications including dyspepsia 11/109 (10.1 %), chest discomfort 27/109 (25 %) and minor gastric bleeding 2/109 (1.8 %) [29]. There were no perforations, strictures, new onset dysphagia, bleeding or death reported [26,28].…”

Section: Strettasupporting

confidence: 85%

“…The procedure is performed in the outpatient setting. Stretta was shown to be safe in several series with only minor complications reported [28,29]. These self-limited complications occurred in 10 (8.6 %) of patients and included fever in two patients, superficial mucosal injury due to catheter movement in three patients (2.5 %) and chest pain requiring narcotic use in two (1.7 %).…”

Section: Strettamentioning

confidence: 99%

See 1 more Smart Citation

New Options for the Management of GERD

Wilson

Louie

2014

Curr Surg Rep

View full text Add to dashboard Cite

Novel GERD treatment modalities have emerged over the past decade as alternatives to proton pump inhibitors or traditional laparoscopic Nissen fundoplication. Four new devices-LINX, TIF, EndoStim and Stretta-have attempted to improve upon the limitations of these traditional therapies. While each is promising, only the LINX device addresses the patient's symptoms, achieves objective control of acid and has limited the need for additional therapies. Further comparative research and longer term follow-up are necessary to determine the role of these therapies in the algorithm of GERD management.

show abstract

Section: Strettasupporting

confidence: 85%

Section: Strettamentioning

confidence: 99%

New Options for the Management of GERD

Wilson

Louie

2014

Curr Surg Rep

View full text Add to dashboard Cite

show abstract

“…Radiofrequency application (Stretta; Curon Medical, Fremont, CA) is designed to increase the reflux barrier of the LES. The open-label, 1-yr follow-up of the first cohort of patients treated with this technique has been recently reported (131). The symptom score related to heartburn improved initially in most patients and this improvement persisted.…”

Section: Level Of Evidence: IIImentioning

confidence: 99%

Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease

DeVault

Castell

2005

Am J Gastroenterology

Self Cite

799

493

View full text Add to dashboard Cite

“…Triadafilopoulos et al [3] reported the results of an initial US open-label study of radiofrequency delivery first to 47 (6 months) patients and subsequently to 118 patients (12-month follow-up). Significant improvement of heartburn symptoms and quality-of-life scores was documented.…”

Section: Radiofrequency Energymentioning

confidence: 99%

Treatment of Gastroesophageal Reflux Disease: Endoscopic Aspects

Špičák

2007

Dig Dis

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) is a very common chronic disorder manifesting itself as heartburn, regurgitation, or dysphagia, possibly leading to esophagitis, Barrett’s esophagus and adenocarcinoma, and has a major impact on the patient’s quality of life. Both medical treatment and surgery are well-established methods with several limitations. Recently, three types of endoscopic methods in several modifications have been developed: (1) Radiofrequency therapy (Stretta procedure) is available both in Europe and USA and more than 5,000 patients have been treated to date. (2) Injection therapy requires the injection of bulking agents or implantation of bioprosthesis into the lower esophageal sphincter (LES) zone. Both Enteryx was withdrawn from the market in 2005, and Gatekeeper was suspended before FDA approval. (3) Suturing/plication therapy is based on the plication at the level of the LES, and most of all techniques resemble the principle of surgical treatment. Despite sophisticated technologies and promising short-term results, all these techniques are associated with inconsistencies, controversies, and relevant adverse affects. According to current practice, use of endoscopic methods is justifiable only as part of clinical trials. Many aspects, including commercial ones, will influence future developments in this area, which are difficult to predict.

show abstract

The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the U.S. open label trial

Cited by 246 publications

References 19 publications

New Options for the Management of GERD

New Options for the Management of GERD

Updated Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease

Treatment of Gastroesophageal Reflux Disease: Endoscopic Aspects

Contact Info

Product

Resources

About